Transitioning Treatment in Diabetic Retinopathy

0.75 CME
45 MINS
$0 FEE
SAVE
Transitioning Treatment in Diabetic Retinopathy

Overview

Provider Statement

This continuing medical education activity is provided by Vindico Medical Education


Support Statement

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. 


Target Audience

The intended audience for the activity is ophthalmologists and other health care professionals involved in the management of patients with diabetic retinopathy.


Learning Objective

Upon successful completion of this activity, participants should be better able to:

  • Evaluate new clinical evidence regarding the treatment of proliferative and nonproliferative diabetic retinopathy.
  • Assess new findings pertaining to the optimization of dosing and management in patients with diabetic retinopathy.

Moderator

David M. Brown, MD, FACS
Clinical Professor of Ophthalmology
Baylor College of Medicine
Retina Consultants of Houston
Director of Clinical Research
Houston, TX


Faculty

W. Lloyd Clark, MD
Palmetto Retina Center, LLC
Assistant Clinical Professor of Ophthalmology
University of South Carolina School of Medicine
Columbia, SC


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.

The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.


Moderator and Faculty report the following relationship(s)

David M. Brown, MD, FACS
Consulting Fee: Allergan, Apellis, Boehringer Ingelheim, Chengdu Kanghong Biotechnology, Clearside, Gemini Therapeutics, Genentech/Roche, Graybug, Heidelberg, Kodiak, Novartis, Ohr, Optos, Regeneron/Bayer, Regenxbio, Santen, Senju, Stealth Biotherapeutics, Zeiss
Contracted Research: Allergan, Apellis, Boehringer Ingelheim, Chengdu Kanghong Biotechnology, Clearside, Gemini Therapeutics, Genentech/Roche, Graybug, Heidelberg, Kodiak, Novartis, Ohr, Optos, Regeneron/Bayer, Regenxbio, Santen, Senju, Stealth Biotherapeutics, Zeiss

W. Lloyd Clark, MD
Consulting Fee: Genentech/Roche, Regeneron
Speakers Bureau: Genentech/Roche, Regeneron
Contracted Research: Genentech/Roche, Regeneron 


Reviewer reports the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.


Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.


Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA–approved or investigational use of products/devices.


Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, July 19, 2019 to July 18, 2020.


How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the CME posttest and evaluation in their entirety. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.


Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.


CME Questions?

Contact us at CME@VindicoCME.com